Patents Assigned to Point Therapeutics
  • Cyclic boroproline compounds
    Patent number: 6355614
    Abstract: Substantially pure preparations of cyclic boroProline compounds that bind, in cyclic or linear form, to CD26 are provided. Methods for using the cyclic compounds to stimulate the activation and/or proliferation of immune cells to achieve preselected normal in vivo levels of these cells also are provided. Evidence of the oral bioavailability and activity of a preferred cyclic compound, valine-prolineboronic acid (ValboroPro), also is provided.
    Type: Grant
    Filed: May 14, 1999
    Date of Patent: March 12, 2002
    Assignee: Point Therapeutics
    Inventor: Barbara P. Wallner